Breast cancer stage I

4 clinical trials

Quick filters

Clinical trials for Breast cancer stage I

4 trials across Europe

See all trials →

Quick filters

4 Clinical trials

Breast cancer stage III+2

Recruiting

Registered drugNo placebo

Study on Pre-Operative Treatment for Breast Cancer Using Nivolumab, Ipilimumab, and Relatlimab for Patients with Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Triple negative breast cancer+4

Recruiting

Registered drugNo placebo

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Breast cancer+2

Recruiting

Registered drugNo placebo

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Institut Gustave Roussy

Contact Research Centre

Breast cancer+7

Not recruiting

Registered drugNo placebo

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:GBG Forschungs GmbH

Contact Research Centre

See all trials →

Breast cancer stage I

Clinical trials for Breast cancer stage I

Breast cancer stage III+2

Study on Pre-Operative Treatment for Breast Cancer Using Nivolumab, Ipilimumab, and Relatlimab for Patients with Breast Cancer

Triple negative breast cancer+4

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Breast cancer+2

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Breast cancer+7

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.